Co-Diagnostics Scales Global Molecular Diagnostic Reach with New Cloud Infrastructure in India
SALT LAKE CITY, Sept. 3, 2026 — Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostic technologies, has officially announced the launch of its integrated cloud infrastructure in India. This strategic deployment marks a significant milestone for the company, providing the essential digital architecture required to support ongoing clinical trials for its Mycobacterium tuberculosis (MTB) point-of-care test while laying the groundwork for the future rollout of the Co-Dx® PCR platform across the nation.
Bridging the Gap in Decentralized Testing
The new infrastructure is designed to overcome one of the most persistent hurdles in global health diagnostics: reliable connectivity. By utilizing a localized cloud environment that adheres to India’s rigorous data privacy and cybersecurity standards, the system allows for mobile-based test analysis in remote or decentralized settings.
The platform’s design ensures that even in areas with limited internet access, results can be generated locally on a mobile device and subsequently synchronized to the cloud once connectivity is restored. This “store-and-forward” capability is a critical component of the company’s efforts to increase diagnostic accessibility in underserved regions.
A Foundation for Public Health and AI
Beyond immediate testing support, the initiative represents a move toward high-value data analytics. As the company expands internationally—with plans to replicate the India model in the Kingdom of Saudi Arabia and South Africa—the integrated ecosystem aims to transform raw diagnostic data into actionable public health intelligence.
“Early on in the platform’s development, we realized that simply increasing access to testing wasn’t enough,” said Dwight Egan, CEO of Co-Diagnostics. “We built an integrated ecosystem that combines our PCR technology, mobile application, and a secure cloud infrastructure to support high-quality molecular diagnostics in decentralized settings.”
The company intends to leverage this aggregated, anonymized data to train its proprietary Co-Dx Primer Ai™ models. These AI-driven tools are designed to enhance real-time disease monitoring and improve outbreak prediction capabilities, potentially creating new revenue streams through data commercialization strategies that support public health initiatives.
Strategic Funding and Future Outlook
The deployment in India, which utilizes the PCR Pro® instrument for sample processing, has been supported in part by funding from the Gates Foundation.
While the platform holds transformative potential for global health, Co-Diagnostics emphasizes that its technology remains subject to regulatory oversight. The Co-Dx PCR platform—which includes the PCR Home®, PCR Pro®, and associated mobile applications—has not yet been cleared or authorized by the FDA or other regulatory bodies and is not currently available for sale.
As the company moves forward, it remains focused on navigating the complex regulatory environments of its target markets while scaling its digital architecture to meet the growing demand for rapid, accurate, and accessible molecular diagnostics.
Disclaimer: This article contains forward-looking statements involving risks and uncertainties. Investors should review the company’s filings with the SEC for a detailed description of the risks associated with its international operations, regulatory hurdles, and commercialization strategies.
